Market Overview

Mylan Pharma Wins Final FDA Approval for ANDA for Phenytoin Chewable Tablets, 50 mg

Share:
Related MYL
Is It Closing Time At The Biotech Bar?
Benzinga's M&A Chatter for Wednesday March 11, 2015
MedTech M&As Continue Regardless of Tax Scenarios - Industry Outlook (Zacks)
Related PFE
SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms
Pfizer Pushes Through Key Resistance Level
The Biogen Alzheimer's Drug is Still a Long Shot (BIIB, PFE, RHHBY, LLY, JNJ) (Small Cap Network)

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Phenytoin Chewable Tablets USP, 50 mg. This product is the generic version of Pfizer's Dilantin® Chewable Tablets, which are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments.

Posted-In: News FDA

 

Related Articles (MYL + PFE)

Around the Web, We're Loving...